Skip to content

Cardiovascular Research Center · Mass General

Seeing vascular disease molecule by molecule.

We build molecular imaging agents and intravascular catheters that reveal inflammation and thrombosis inside living arteries.

Diseases
Atherosclerosis · Thrombosis · AVF
Scale
Mouse → large animal → human
Signal
Near-infrared fluorescence

The lab at a glance

0+

Citations across the lab's published work

0

h-index

0

Papers cited 10+ times (i10-index)

0

Indexed works, including papers, abstracts and patents

Source: Google Scholar

Affiliations & partners

Massachusetts General HospitalHarvard Medical SchoolMGH Cardiovascular Research CenterWellman Center for PhotomedicineCABBINIH-funded research

01 — Research

Making biology visible in vivo.

With molecular imaging chemists and engineers, we image the cells and enzymes that drive plaque rupture, clotting and vessel failure — and learn how these lesions form and resolve.

R.01

Plaque inflammation

Agents that report macrophage activity and cathepsin protease activity, flagging plaques at higher risk.

R.02

Thrombosis & fibrin

Imaging fibrin, thrombin and activated factor XIII to watch clots form, mature and resolve in real time.

R.03

Endothelial activation

Targeting VCAM-1 to read the earliest inflammatory signals on the vessel wall, before plaques mature.

R.04

Arteriovenous fistula

Understanding why dialysis access fails, by imaging inflammation and remodeling as fistulas form.

R.05

High-risk plaques & stents

Intravascular NIRF catheters that pair molecular signal with structure in human-sized coronary arteries and stents.

R.06

Better coronary intervention

Clinical research to raise success in chronic total occlusion PCI, radial access and microvascular angina.

02 — Bench to bedside

From molecule to patient.

One continuous pipeline, from probe design through mouse models and large animals to the cardiac catheterization lab.

  1. 01

    Chemistry

    Design the probe

    Build agents that light up a single biological target: a cell, an enzyme, a clot protein.

  2. 02

    Murine models

    Image living disease

    Quantify targets with intravital microscopy, FMT, MRI and PET-CT as lesions evolve.

  3. 03

    Large animals

    Scale the catheter

    Validate NIRF-OCT and NIRF-IVUS imaging in coronary-sized arteries and stents.

  4. 04

    Clinic

    Reach the patient

    Image human coronary arteries in the cath lab, aiming to catch high-risk disease earlier.

03 — Imaging platforms

Our imaging toolkit.

Hover or tap a platform for what it lets us see.

Placeholder: laboratory research imagery

Flagship · Intravascular

NIRF-OCT

Near-infrared fluorescence fused with optical coherence tomography: molecular signal and microstructure captured together in one pullback.

Nature Medicine, 2011 ↗
Placeholder: medical imaging

Intravascular

NIRF-IVUS

Molecular fluorescence paired with ultrasound depth for full-wall coronary imaging.

EHJ Cardiovasc Imaging, 2017 ↗
Placeholder: microscopy

Preclinical

Intravital microscopy

Cell-level views of clots and plaques forming in living tissue.

Integrative Biology, 2013 ↗
Placeholder: anatomical imaging

Whole body

FMT · MRI · PET-CT

Quantitative 3D molecular imaging across the whole animal.

ATVB, 2009 ↗
Placeholder: clinical procedure room

Clinical

CTO PCI program

Opening complete coronary blockages, including CT overlay on live angiography.

Watch: MGH Advances video ↗

04 — Highlights

Milestones that moved the field.

06 — People

Physicians, scientists, engineers.

  1. 1990

    BS with distinction, Mathematical & Computational Sciences — Stanford University

  2. 1993–1995

    HHMI–NIH Research Scholar

  3. 1996

    MD and PhD in Biophysics — University of Pennsylvania School of Medicine

  4. 1999–2001

    Medicine residency, Brigham and Women's Hospital; cardiology fellowship, MGH

  5. Postdoc

    Center for Molecular Imaging Research, MGH; interventional cardiology fellowship

  6. 2003–2007

    MGH Cardiology faculty · HMS Assistant Professor · CVRC Principal Investigator

  7. 2011–2013

    Wellman Center affiliate · HMS Associate Professor · elected to the ASCI

The team

The people behind the pullbacks.

  • Instructor · 2021–present

    Aatira Vijay, PhD

    Post-thrombotic syndrome and vein wall scarring, studied with intravital imaging.

  • Instructor · 2019–present

    Mohamad Kassab, MD

    How therapeutics change inflammation in cardiovascular disease and arteriovenous fistula, read out by molecular imaging.

  • Lab manager · 2012–present

    Adam Mauskapf

    Runs lab operations and supports the preclinical imaging studies.

  • Postdoctoral fellow · 2025–present

    Shang Gao, PhD

    Optical and acoustic imaging technologies for cardiovascular diagnosis and treatment.

  • Postdoctoral fellow · 2025–present

    Tao Qiu, MD, PhD

    Therapeutic effects on cardiovascular inflammation, assessed by molecular imaging.

  • Postdoctoral fellow · 2024–present

    Mahira Kaabeche, PhD

    How stress and depression affect thrombosis and the vein wall.

  • Postdoctoral fellow · 2024–present

    Burak Cilhoroz, PhD

    Intravital and multiphoton imaging of vascular inflammation in atherosclerosis models.

  • Now recruiting

    Research Fellow, Atherosclerosis Inflammation

    See how to apply

Alumni

Where our trainees lead next.

Former fellows now run labs, imaging cores and cath labs across three continents.

  • Wenzhu Li, MD2016–2021Associate Professor, Ruijin Hospital & Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine
  • Eric Osborn, MD, PhD2013–2020Assistant Professor of Medicine & Interventional Cardiologist, Beth Israel Deaconess Medical Center
  • Chase Kessinger, PhD2009–2018Assistant Professor of Cardiovascular Medicine & Imaging Core Director, Masonic Medical Research Institute
  • Tetsuya Hara, MD, PhD2010–2014Assistant Professor, Kobe University, Japan
  • Madeleine Grau2017–2019Research technician
  • Harkamal Jhajj2015–2017Research technician
  • Brian Thompson2010–2011Research technician · now a company CEO

07 — Publications

Selected work.

Full list on NCBI
  • 2011 · Nat MedIntra-arterial catheter for simultaneous microstructural and molecular imaging in vivoYoo H, Kim JW, … Jaffer FA, Tearney GJ · Nature Medicine 17(12)389 cites
  • 2011 · Sci Transl MedIndocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaquesVinegoni C, Botnaru I, Aikawa E, Calfon MA, … · Science Translational Medicine 3(84)260 cites
  • 2016 · JACC CVIClinical characterization of coronary atherosclerosis with dual-modality OCT and near-infrared autofluorescence imagingUghi GJ, Wang H, Gerbaud E, Gardecki JA, … · JACC: Cardiovascular Imaging 9(11)240 cites
  • 2016 · JACC CVITargeted near-infrared fluorescence imaging of atherosclerosis: clinical and intracoronary evaluation of indocyanine greenVerjans JW, Osborn EA, Ughi GJ, Calfon Press MA, … · JACC: Cardiovascular Imaging 9(9)132 cites
  • 2011 · JACCTwo-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injuryJaffer FA, Calfon MA, Rosenthal A, Mallas G, … · J Am Coll Cardiol 57(25)208 cites
  • 2004 · CirculationMolecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombiJaffer FA, Tung CH, Wykrzykowska JJ, … · Circulation 110(2)157 cites
  • 2002 · ATVBIn vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probeJaffer FA, Tung CH, Gerszten RE, Weissleder R · Arterioscler Thromb Vasc Biol 22(11)174 cites
  • 2012 · JACC CVIMolecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescenceHara T, Bhayana B, Thompson B, Kessinger CW, … · JACC: Cardiovascular Imaging 5(6)117 cites
  • 2017 · Eur Heart JIntravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivoHara T, Ughi GJ, McCarthy JR, Erdem SS, … · European Heart Journal 38(6)86 cites
  • 2020 · JASNAtorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistulaCui J, Kessinger CW, Jhajj HS, Grau MS, … · J Am Soc Nephrol 31(5)20 cites
  • 2006 · CirculationNoninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosisNahrendorf M, Jaffer FA, Kelly KA, … · Circulation 114(14)939 cites
  • 2007 · CirculationOptical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensorJaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, … · Circulation 115(17)316 cites
  • 2005 · JAMAMolecular imaging in the clinical arenaJaffer FA, Weissleder R · JAMA 293(7)517 cites
  • 2007 · CirculationOsteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivoAikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, … · Circulation 116(24)879 cites
  • 2006 · PNASMonocyte accumulation in mouse atherogenesis is progressive and proportional to extent of diseaseSwirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, … · PNAS 103(27)485 cites
  • 2019 · CirculationGuiding principles for chronic total occlusion percutaneous coronary intervention: a global expert consensus documentBrilakis ES, Mashayekhi K, Tsuchikane E, … · Circulation 140(5)543 cites
  • 2016 · JACC CIDevelopment and validation of a novel scoring system for predicting technical success of CTO PCI: the PROGRESS CTO scoreChristopoulos G, Kandzari DE, Yeh RW, Jaffer FA, … · JACC: Cardiovascular Interventions 9(1)452 cites
  • 2021 · CirculationDefinitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC consensus recommendationsYbarra LF, Rinfret S, Brilakis ES, … · Circulation 143(5)372 cites
  • 2020 · JACCReduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemicGarcia S, Albaghdadi MS, Meraj PM, … Jaffer FA, … · J Am Coll Cardiol 75(22)1,488 cites

Technology & patents

More: Google Scholar · PubMed · First-in-human NIRAF-OCT (2016) · Intravascular NIRF review (2020)

08 — Work with us

Three ways in.

We train at the interface of cardiology, chemistry, optics and engineering.

Track A

Students & research fellows

Undergraduate, graduate and medical students seeking hands-on imaging research.

  • →Preclinical imaging projects
  • →Image analysis & quantification
  • →Mentored by physician-scientists
Enquire
Core track

Track B

Postdocs & clinical fellows

PhDs and MDs ready to lead translational molecular imaging projects.

  • →Lead bench-to-bedside studies
  • →Intravascular catheter imaging
  • →Grant writing & first-author papers
Apply to the lab

Track C

Collaborators & industry

Chemists, engineers and companies advancing vascular imaging.

  • →Imaging agent co-development
  • →Catheter & system validation
  • →Large-animal & clinical studies
Start a conversation

09 — FAQ

Questions, answered.

A catheter inside the artery detects near-infrared light from targeted imaging agents or natural autofluorescence. Combined with OCT or IVUS, it shows both what a plaque looks like and what it is doing biologically.

Heart attacks, strokes and venous clots are driven by biology that structural imaging alone can miss. Seeing macrophages, proteases and fibrin directly could help identify high-risk plaques and stents earlier.

Send your CV, a short statement of research interests and two references through the contact form below or by email. Please mention which track you are applying for.

For clinical care, including chronic total occlusion PCI, please call the clinical office at 617-724-8052. The research lab cannot give medical advice.

Yes. Our catheters and systems were developed with engineering and chemistry partners. Reach out through the research office to discuss agents, devices or studies.

10 — Contact

Help us see disease sooner.

Trainees, collaborators and partners: tell us who you are and what you'd like to explore.

Or write directly to fjaffer@mgh.harvard.edu · Research office 617-724-9353 · Patients: 617-724-8052